In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
ApexOnco Front Page
Recent articles
The private ADC company is being wound down.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
